This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moore, C. B.
Right arrow Articles by Denning, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moore, C. B.
Right arrow Articles by Denning, D. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2001, p. 1882-1885, Vol. 45, No. 6
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.6.1882-1885.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

In Vitro Activities of Terbinafine against Aspergillus Species in Comparison with Those of Itraconazole and Amphotericin B

Caroline B. Moore,1 Caroline M. Walls,1,dagger and David W. Denning2,3,4,*

Departments of Microbiology1 and Medicine,2 Hope Hospital, Salford, Department of Infectious Diseases and Tropical Medicine, North Manchester General Hospital,3 and University of Manchester,4 Manchester, United Kingdom

Received 11 September 2000/Returned for modification 4 January 2001/Accepted 5 March 2001

Compared with the in vitro activities of itraconazole (geometric mean MIC [GM], 0.56 µg/ml) and amphotericin B (GM, 0.66 µg/ml), the in vitro activity of terbinafine was inferior against Aspergillus fumigatus (GM, 19.03 µg/ml) (P < 0.05) and superior against A. flavus (GM, 0.10 µg/ml), A. terreus (GM, 0.16 µg/ml), and A. niger (GM, 0.19 µg/ml). Clinical correlation is required, as trailing endpoints are problematic.


* Corresponding author. Mailing address: Department of Infectious Diseases and Tropical Medicine, North Manchester General Hospital, Delaunays Rd., Manchester M8 6RB, United Kingdom. Phone: (44) 161 720 2734. Fax: (44) 161 720 2732. E-mail: ddenning{at}man.ac.uk.

dagger Present address: Health & Safety Executive, Magdalen House, Stanley Precinct, Bootle, Merseyside, L20 3QZ, United Kingdom.


Antimicrobial Agents and Chemotherapy, June 2001, p. 1882-1885, Vol. 45, No. 6
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.6.1882-1885.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Steinbach, W. J., Perfect, J. R., Schell, W. A., Walsh, T. J., Benjamin, D. K. Jr. (2004). In Vitro Analyses, Animal Models, and 60 Clinical Cases of Invasive Aspergillus terreus Infection. Antimicrob. Agents Chemother. 48: 3217-3225 [Full Text]  
  • Canton, E., Peman, J., Gobernado, M., Viudes, A., Espinel-Ingroff, A. (2004). Patterns of Amphotericin B Killing Kinetics against Seven Candida Species. Antimicrob. Agents Chemother. 48: 2477-2482 [Abstract] [Full Text]  
  • Garcia-Effron, G., Gomez-Lopez, A., Mellado, E., Monzon, A., Rodriguez-Tudela, J. L., Cuenca-Estrella, M. (2004). In vitro activity of terbinafine against medically important non-dermatophyte species of filamentous fungi. J Antimicrob Chemother 53: 1086-1089 [Abstract] [Full Text]  
  • Pfaller, M. A., Sheehan, D. J., Rex, J. H. (2004). Determination of Fungicidal Activities against Yeasts and Molds: Lessons Learned from Bactericidal Testing and the Need for Standardization. Clin. Microbiol. Rev. 17: 268-280 [Abstract] [Full Text]  
  • Mosquera, J., Sharp, A., Moore, C. B., Warn, P. A., Denning, D. W. (2002). In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp.. J Antimicrob Chemother 50: 189-194 [Abstract] [Full Text]